MedTrace Logo

The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia

NCT00846703 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2010-03-08

No results posted yet for this study

Summary

The Guangdong work group of childhood acute lymphoblastic leukemia (ALL) therapy was set up in October 2002. The investigators treated the childhood ALL with a GZ2002 protocol since the year 2002, and the protocol was mainly derived from the ALLIC-BFM 2002 protocol. After summarizing the last six years' experience, our group revised the GZ2002 ALL protocol in the year 2008, which is named GD-2008 ALL protocol. The diagnosis and classified criteria is according to the ALLIC-BFM 2002 protocol, and the chemotherapy protocol consists all the therapeutic phases as the ALLIC-BFM 2002 protocol prescribed.

Conditions

Interventions

DRUG

6-mercaptopurine, Methotrexate

6-mercaptopurine p.o. qd Methotrexate p.o. qw

DRUG

6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone

(1)6-mercaptopurine p.o. qd x 7w Methotrexate p.o. qd x 7w (2)Vincristine qw x 1w Dexamethasone p.o. qd x 7d Go to (1) and (2)

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Jianpei Fang, M.D. · Second Affiliated Hospital, Sun Yat-Sen University

  • Xuequn Luo, M.D. · First Affiliated Hospital, Sun Yat-Sen University

  • Jianliang Chen, M.D. · Third Affiliated Hospital, Sun Yat-Sen University

  • Xiaofei Sun · The cancer hospital of Sun Yat-sen University

  • Xuedong Wu · Nanfang hospital of Nanfang Medical University

  • Liming Tu, M.D. · Guangdong Provincial People's Hospital

  • Dongbo Lai, M.D. · Guangzhou children's hospital

  • Changgang Li, M.D. · Shenzhen Children's Hospital

  • Liyang Liu, M.D. · Huizhou People's Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2013-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00846703 on ClinicalTrials.gov